← Back to Clinical Trials
Recruiting Phase 4 NCT04729686

The Pericapsular Nerve Block in Total Hip Arthroplasty

Trial Parameters

Condition Hip Osteoarthritis
Sponsor LifeBridge Health
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 78
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2020-12-09
Completion 2025-12-01
Interventions
Pericapsular Nerve BlockFascia Iliaca Nerve Block

Brief Summary

In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fascia iliaca nerve block.

Eligibility Criteria

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Planned primary total hip arthroplasty with anterior (Smith-Peterson) approach * ASA score of 1 to 3 * Indicated for one of the two nerve block groups * Must be opioid naïve at screening as defined by the FDA - According to the Food and Drug Administration, opioid-tolerant patients were those currently receiving or who had previously received 60 mg PO morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg PO oxycodone per day, 8 mg PO hydromorphone per day, 25 mg PO oxymorphone per day, 60 mg PO hydrocodone per day, or an equivalent dose of another opioid for a duration of one week or longer (16) Exclusion Criteria: * Current or previous diagnosis of "chronic pain" * Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily,

Related Trials